Pharmaceutical Samples

PMS 327
Teal
BlackPMS 641
Blue
Information/
Dieline
No
Varnish
Printed at
Magniﬁcation
Bar Code: NDC Number
Type: UPC (A)
Magnif.: 102.56%
BWR: 2.5 mils
Encoded: 352544622010
Description: Bottle Label, Microzide 12.5mg x 100
Item No. (JDE): 202246 Drawing No. (Artwork): 174782-2 PLECR No.: 110056bS
Technicial Drawing No.: Artist: K. Kynaston
Dimensions: 4.750” W x 1.750” H; UVA 0.640” x 1.234”
Approval Signatures
Proprietary Labeling • Watson Laboratories, Inc. • Salt Lake City, UT 84108 • (801) 588-6200
PMS Warm
Gray #9 DateAuthorizedtoDisseminate:________/________/_______
Signed:_____________________________Date:___________
LOTNO.:
EXP.:
NDC 52544-622-01
ManufacturedBy:
WatsonPharmaPrivateLimited
Verna,SalcetteGoa403722INDIA
Capsules
12.5 mg(hydrochlorothiazide,USP)
12.5 mg
EACH CAPSULE CONTAINS:
Hydrochlorothiazide, USP.......12.5 mg
Rx only
100 Capsules
174782-2
Dispense in a tight, light-resistant
container as deﬁned in the USP.
USUAL DOSAGE:
See package insert for full
prescribing information.
Keep out of reach of children.
Store at 20°-25°C (68°-77°F).
[See USP controlled room
temperature.] Protect from light,
moisture, freezing, -20°C (-4°F).
Code No. GO/DRUGS/741
Distributed By: Watson Pharma, Inc.

ulipristalacetate
tablet30mg
ulipristal acetate
tablet 30 mg
Distributed By:
Watson Pharma, Inc.; Parsippany, NJ 07054 USA
Under License From:
Laboratoire HRA Pharma; 75003 Paris, France
Manufactured By:
Cenexi, 95520 Osny, France; or
Laboratorios León Farma S.A.
24008 León, Spain
LOT:
EXP:
ulipristalacetate
tablet30mg
Dose Age
17yearsofage
orolder
Takeonetabletassoonaspossiblewithin5days(120
hours)afterunprotectedsexorbirthcontrolfailure
Dose Age
16yearsofage
andyounger
Seeahealthcareprofessional.Women16yearsofage
andyoungerneedadoctor’sprescription.
DrugFacts
ActiveingredientPurpose
ulipristalacetate30mg........................................Emergencycontraceptive
Usereduceschanceofpregnancyafterunprotectedsex(ifacontraceptivefailed
orifyoudidnotusebirthcontrol)
Warnings
Allergyalert:Donotuseifyouhaveeverhadanallergicreactionto
ulipristalacetate
Sexuallytransmittedinfections(STIs)alert:Thisproductdoesnot
protectagainstHIV/AIDSorotherSTIs
Donotusesifyouhadunprotectedintercoursemorethan5days
(120hours)agosmorethanonetimeinthesamemenstualcycle
sforregularbirthcontrol
Whenusingthisproductyoumayhave:
sheadachesmenstrualpainsdizzinesssnausea
stirednesssstomachpainsacnesmenstrualbleeding
Whenpregnantorbreast-feedingsdonotuse
sifyoucouldalreadybepregnant(forexample,youhadalateormissed
period),youshoulddoapregnancytestorspeakwithahealthcare
professionalbeforetakingthismedication
Keepoutofreachofchildren.Incaseofoverdose,getmedicalhelpor
contactaPoisonControlcenterrightaway
Directions
Ifyouvomitwithin3hoursoftakingthemedication,calla
healthcareprofessionaltoﬁndoutifyoushouldrepeatthedose
Ifyouhavesexagaininthesamemenstrualcycle:useareliable
barriermethod(suchasacondomwithspermicide),evenifyouare
usinghormonalbirthcontrol(patch,pill,orring).Yourregular
hormonalbirthcontrolmaynotworkaswellfortheremainderof
yourmenstualcycleafteryoutakethisproduct.
Otherinformation
sbeforeusingthisproductreadtheenclosedconsumerinformation
leaﬂetforcompletedirectionsandinformation
sthisproductmaycauseyourperiodtooccurearlierorlaterthan
expectedbyafewdays
sthisproductworksmainlybypreventingovulation(eggrelease).Itmay
alsopreventimplantation(attachment)ofafertilizedeggtotheuterus.
slatexcondoms,whenusedcorrectlyeverytimeyouhavesex,greatly
reduce(butdonoteliminate)theriskofpregnancyandtheriskof
gettingorspreadingHIV,thevirusthatcausesAIDS.Seecondom
labelingformoreSTIinformation.
skeepthetabletintheblistersealinthiscartonuntilyouarereadyto
takeit.Donotuseiftheblistersealisbroken.
sstoreat68-77°F(20-25°C)
Inactiveingredients
croscarmellosesodium,lactosemonohydrate,
magnesiumstearate,andpovidone
DrugFacts(Continued)
DrugFacts(Continued)
¤Questionsorcomments?
Formoreinformationortospeaktoahealthcareprofessional,call1-800-272-5525,24hoursaday/7daysaweek.Visitourwebsiteatwww.XXXX.com
ulipristal acetate
tablet 30 mg
Reduces the chance of pregnancy after unprotected
sex or birth control failure. Not for regular birth
control use. Use only in emergencies.
Take one tablet as soon as possible within 5 days (120 hours)
after unprotected sex or birth control failure.
Emergency Contraceptive Tablet
Each tablet contains 30 mg ulipristal acetate1
Rx only for women
younger than age 17
NDC 52544-XXX-XX

Black Information/
Dieline
Printed at
Magniﬁcation
Bar Code: NDC Number
Type: GS1 Data Bar
Magnif.: N/A
X-Dimen: 9.2 mils
Encoded: 00352544238549
Description: Foil, ella, 30 mg
Item No. (JDE): N/A Drawing No. (Artwork): 515120 PLECR No.: 110054cS
Technical Drawing No.: Catalent 36013-A3 Artist: K. Kynaston
Dimensions: 1.890" W x 1.890" L (48 x 48mm); UVA N/A
Approval Signatures
Proprietary Labeling • Watson Laboratories, Inc. • Salt Lake City, UT 84108 • (801) 588-6200
DateAuthorizedtoDisseminate:________/________/_______
Signed:_____________________________Date:___________
Contains 1
30 mg tablet
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
Parsippany, NJ 07054 USA
N 52544-238-54
515120
ulipristal acetate tablet 30 mg
Contains 1
30 mg tablet
515120
Contains 1
30 mg tablet
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
N 52544-238-54
Contains 1
30 mg tablet515120
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
N 52544-238-54
515120
Contains 1
30 mg tablet
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
N 52544-238-54
Contains 1
30 mg tablet
515120
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
N 52544-238-54
515120
Contains 1
30 mg tablet
LOT:
EXP:
Push through
from front
Distributed By:
Watson Pharma, Inc.
N 52544-238-54

• ANDRODERM is to be applied to your back,
stomach area (abdomen), upper arms, or thighs
only (See Figure A and Figure B). Do not apply
ANDRODERM to any other parts of your body such
as your scrotum, buttocks or over a bony area.
1. Open the foil pouch.
Tear along the edge
and remove the patch
from the pouch (See
Figure C).
Do not cut the
ANDRODERM
protective pouch.
*Sections or subsections omitted from the full prescribing information are not listed
FULL PRESCRIBING INFORMATION: CONTENTS*
PATIENT INFORMATION
ANDRODERM®
(an-dro-derm) CIII
(testosterone transdermal system)
for topical use
Read this Patient Information before you start taking
ANDRODERM and each time you get a refill. There may
be new information. This information does not take the
place of talking with your healthcare provider about
your medical condition or your treatment.
What is ANDRODERM?
ANDRODERM is a prescription medicine that contains
testosterone. ANDRODERM is used to treat adult males
who have low or no testosterone.
Your healthcare provider will test your blood for
testosterone before you start and while you are taking
ANDRODERM.
It is not known if ANDRODERM is safe and effective in
children younger than 18 years old. Improper use of
ANDRODERM may affect bone growth in children.
ANDRODERM is a controlled substance (CIII) because
it contains testosterone that can be a target for people
who abuse prescription medicines. Keep your
ANDRODERM in a safe place to protect it. Never give
your ANDRODERM to anyone else, even if they have the
same symptoms you have. Selling or giving away this
medicine may harm others and it is against the law.
ANDRODERM is not meant for use by women.
Who should not use ANDRODERM?
Do not use ANDRODERM if you:
• are a man who has breast cancer
• have or might have prostate cancer
• are pregnant or may become pregnant or are
breastfeeding. ANDRODERM may harm your unborn
or breastfeeding baby.
Talk to your healthcare provider before taking this
medicine if you have any of the above conditions.
What should I tell my healthcare provider before
using ANDRODERM?
Before you use ANDRODERM, tell your healthcare
provider if you:
• have breast cancer
• have or might have prostate cancer
• have urinary problems due to an enlarged prostate
• have heart problems
• have kidney or liver problems
• have problems breathing while you sleep (sleep apnea)
• have diabetes
• have any other medical conditions
Tell your healthcare provider about all the medicines
you take, including prescription and non-prescription
medicines, vitamins, and herbal supplements.
Using ANDRODERM with other medicines can affect
each other. Especially, tell your healthcare provider if
you take:
• insulin
• medicines that decrease blood clotting
• corticosteroids
Know the medicines you take. Ask your healthcare
provider or pharmacist for a list of all your medicines if
you are not sure. Keep a list of them and show it to your
healthcare provider and pharmacist when you get a new
medicine.
How should I use ANDRODERM?
• It is important that you apply ANDRODERM exactly
as your healthcare provider tells you to.
• ANDRODERM patches come in 2 different doses and
different patch sizes.
• Your healthcare provider will tell you how many
ANDRODERM patches to apply and when to apply them.
• Your healthcare provider may change your
ANDRODERM dose. Do not change your
ANDRODERM dose without talking with your
healthcare provider.
• Apply ANDRODERM at about the same time each night.
• Wait 3 hours before showering, bathing, or
swimming. This will ensure that the greatest amount
of ANDRODERM is absorbed into your system.
• ANDRODERM does not need to be removed during
sex or while you take a shower or bath.
• Strenuous exercise or excessive perspiration may
loosen your ANDRODERM patch or cause it to fall off.
• If your ANDRODERM patch becomes loose, smooth
it down again by rubbing your finger firmly around
the edges. Do not tape ANDRODERM patches to
your skin.
• If your ANDRODERM patch falls off before noon,
put on a new ANDRODERM patch and wear it
Printedat
Magnification
BarCode:Manufacturing
Type:Code39
Magnif.:100%
BWR:2.5mils
Encoded:196664-01
BlackInformation/
Dieline
Description:Physician-PatientInsert,AndrodermTTS(US)
ItemNo.(JDE):205052DrawingNo.(Artwork):196664-01PLECRNo.:120014aS
TechnicalDrawingNo.:PharmLithoRTA#97Artist:K.Kynaston
Dimensions:18.000"Wx15.000"H-Flat;3.000"Wx2.500"H-FoldedProprietaryLabeling•WatsonLaboratories,Inc.•SaltLakeCity,UT84108•(801)588-6200
ApprovalSignaturesICE
196664-01
Revised: April 2012
Rx only
PATIENT INFORMATION
196664-01
Revised:April2012
Rxonly
PHYSICIANINFORMATION
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Dosing Information
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Worsening of Benign Prostatic
Hyperplasia and Potential Risk of
Prostate Cancer
5.2 Polycythemia
5.3 Use in Women and Children
5.4 Potential for Adverse Effects on
Spermatogenesis
5.5 Hepatic Adverse Effects
5.6 Edema
5.7 Gynecomastia
5.8 Sleep Apnea
5.9 Lipids
5.10 Hypercalcemia
5.11 Decreased Thyroxine-Binding Globulin
5.12 Magnetic Resonance Imaging (MRI)
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
7.1 Insulin
7.2 Oral Anticoagulants
7.3 Corticosteroids
7.4 Triamcinolone
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
9.2 Abuse
9.3 Dependence
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis,
Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
17.1 Use in Men with Known or
Suspected Prostate or Breast Cancer
17.2 Potential Adverse Reactions with
Androgens
17.3 Patients Should be Advised of these
Application Instructions
FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
ANDRODERM is an androgen indicated for replacement therapy in adult
males for conditions associated with a deficiency or absence of
endogenous testosterone.
• Primary hypogonadism (congenital or acquired): testicular failure
due to conditions such as cryptorchidism, bilateral torsion, orchitis,
vanishing testis syndrome, orchiectomy, Klinefelter Syndrome,
chemotherapy, or toxic damage from alcohol or heavy metals. These
men usually have low serum testosterone concentrations and
gonadotropins (FSH, LH) above the normal range.
• Hypogonadotropic hypogonadism (congenital or acquired):
idiopathic gonadotropin or luteinizing hormone-releasing hormone
(LHRH) deficiency or pituitary-hypothalamic injury from tumors,
trauma, or radiation. These men have low testosterone serum
concentrations but have gonadotropins in the normal or low range.
Important limitations of use – Safety and efficacy of ANDRODERM in
males less than 18 years old have not been established [see Use in
Specific Populations (8.4)].
2 DOSAGE AND ADMINISTRATION
2.1 Dosing Information
The recommended starting dose is one ANDRODERM 4 mg/day system
(not two 2 mg/day systems) applied nightly for 24 hours, delivering
approximately 4 mg of testosterone per day. To ensure proper dosing,
approximately 2 weeks after starting therapy, the early morning serum
testosterone concentration should be measured following system
application the previous evening. Serum concentrations outside the range
of 400 – 930 ng/dL require increasing the daily dose to 6 mg (i.e., one
4 mg/day and one 2 mg/day system) or decreasing the daily dose to 2 mg
(i.e., one 2 mg/day system), maintaining nightly application.
Patients currently maintained on ANDRODERM 2.5 mg/day, 5 mg/day,
and 7.5 mg/day may be switched to the 2 mg/day, 4 mg/day, and
6 mg/day dosage using the following schema:
• Patients using 2.5 mg daily may be switched to 2 mg/day systems at
the next scheduled dose.
• Patients using 5 mg daily may be switched to 4 mg/day systems at
the next scheduled dose.
• Patients using 7.5 mg daily may be switched to 6 mg (2 mg/day and
4 mg/day systems) at the next scheduled dose.
To ensure proper dosing, approximately 2 weeks after switching therapy,
the early morning serum testosterone concentration should be measured
following system application the previous evening.
The adhesive side of the ANDRODERM system should be applied to a
clean, dry area of the skin on the back, abdomen, upper arms, or
thighs. Avoid application over bony prominences or on a part of the
body that may be subject to prolonged pressure during sleep or sitting
(e.g., the deltoid region of the upper arm, the greater trochanter of the
femur, and the ischial tuberosity). DO NOT APPLY TO THE SCROTUM.
The sites of application should be rotated, with an interval of 7 days
between applications to the same site. The area selected should not
be oily, damaged, or irritated.
The system should be applied immediately after opening the pouch and
removing the protective release liner. The system should be pressed firmly
in place, making sure there is good contact with the skin, especially
around the edges.
The patient should avoid swimming, showering, or washing the
administration site for a minimum of 3 hours after application [see Clinical
Pharmacology (12.3)].
Mild skin irritation may be ameliorated by treatment of the affected skin
with over-the-counter topical hydrocortisone cream applied after system
removal. Applying a small amount of 0.1% triamcinolone acetonide cream
to the skin under the central drug reservoir of the ANDRODERM system
has been shown to reduce the incidence and severity of skin irritation.
3 DOSAGE FORMS AND STRENGTHS
Transdermal system: 2 mg/day and 4 mg/day.
4 CONTRAINDICATIONS
• ANDRODERM is contraindicated in men with carcinoma of the breast
or known or suspected carcinoma of the prostate [see Warnings and
Precautions (5.1)].
• ANDRODERM is contraindicated in women who are, or who may
become pregnant, or who are breastfeeding. ANDRODERM may cause
fetal harm when administered to a pregnant woman. ANDRODERM
may cause serious adverse reactions in nursing infants. If a pregnant
woman is exposed to ANDRODERM, she should be apprised of the
potential hazard to the fetus [see Use in Specific Populations (8.1, 8.3)].
5 WARNINGS AND PRECAUTIONS
5.1 Worsening of Benign Prostatic Hyperplasia and Potential Risk
of Prostate Cancer
• Monitor patients with benign prostatic hyperplasia (BPH) for
worsening of signs and symptoms of BPH.
• Patients treated with androgens may be at increased risk for prostate
cancer. Evaluate patients for prostate cancer prior to initiating
treatment. It is appropriate to re-evaluate patients 3 to 6 months after
initiation of treatment, and then in accordance with prostate cancer
screening practices [see Contraindications (4)].
5.2 Polycythemia
Increases in hematocrit, reflective of increases in red blood cell mass, may
require lowering or discontinuation of testosterone. Check hematocrit prior
to initiating testosterone treatment. It is appropriate to re-evaluate the
hematocrit 3 to 6 months after starting testosterone treatment, and then
monitor annually. Discontinue testosterone therapy if the hematocrit
becomes elevated. Testosterone therapy may be restarted when the
hematocrit decreases to an acceptable level. An increase in red blood cell
mass may increase the risk of thromboembolic events.
5.3 Use in Women and Children
Women and children should not use ANDRODERM. Use in women and
children has not been studied with ANDRODERM.
Due to lack of controlled studies in women and potential virilizing effects,
ANDRODERM is not indicated for use in women and children [see
Contraindications (4) and Use in Specific Populations (8.1, 8.3, 8.4)].
5.4 Potential for Adverse Effects on Spermatogenesis
At large doses of exogenous androgens, including ANDRODERM,
spermatogenesis may be suppressed through feedback inhibition of
pituitary follicle-stimulating hormone (FSH) that could lead to adverse
effects on semen parameters including reduction of sperm count.
5.5 Hepatic Adverse Effects
Prolonged use of high doses of orally active 17-alpha-alkyl androgens
(methyltestosterone) has been associated with serious hepatic adverse
effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and
jaundice). Peliosis hepatis can be a life-threatening or fatal complication.
Long-term therapy with intramuscular testosterone enanthate has
produced multiple hepatic adenomas. ANDRODERM is not known to
cause these adverse effects.
5.6 Edema
Androgens, including ANDRODERM, may promote retention of sodium
and water. Edema, with or without congestive heart failure, may be a
serious complication in patients with pre-existing cardiac, renal, or hepatic
disease [see Adverse Reactions (6)].
5.7 Gynecomastia
Gynecomastia may develop and persist in patients being treated with
androgens, including ANDRODERM, for hypogonadism.
5.8 Sleep Apnea
The treatment of hypogonadal men with testosterone may potentiate sleep
apnea in some patients, especially those with risk factors such as obesity
and chronic lung disease.
5.9 Lipids
Changes in serum lipid profile may require dose adjustment or
discontinuation of testosterone therapy.
5.10 Hypercalcemia
Androgens, including ANDRODERM, should be used with caution in
cancer patients at risk of hypercalcemia (and associated hypercalciuria).
Regular monitoring of serum calcium concentrations is recommended in
these patients.
5.11 Decreased Thyroxine-Binding Globulin
Androgens, including ANDRODERM, may decrease concentrations of
thyroxine-binding globulins, resulting in decreased total T4 serum
concentration and increased resin uptake of T3 and T4. Free thyroid
hormone concentration remains unchanged and there is no clinical
evidence of thyroid dysfunction.
5.12 Magnetic Resonance Imaging (MRI)
Skin burns have been reported at the application site in patients wearing
an aluminized transdermal system during a magnetic resonance imaging
scan (MRI). Because ANDRODERM contains aluminum, it is
recommended to remove the system before undergoing an MRI.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot
be directly compared with rates in the clinical trials of another drug
and may not reflect the rates observed in practice.
Table 1 shows the adverse reactions that were reported by > 3% of
36 hypogonadal men who were treated with ANDRODERM 2 mg/day,
4 mg/day, or 6 mg/day for 28 days. Of note, all hypogonadal men
studied had been stable users of topical testosterone replacement
products prior to the study and there was no washout period between
therapies. Furthermore, there was only one subject titrated to
6 mg/day and he withdrew from the study prematurely.
Table 1. Adverse Reactions Seen With the Use of ANDRODERM
2 mg/day, 4 mg/day, or 6 mg/day (> 3%)
Other less common adverse reactions reported by < 3% of patients
included: application site erythema, application site exfoliation, chills,
diarrhea, fatigue, gastroesophageal reflux disease, hemarthrosis,
hematuria, headache, polyuria, and prostatitis. The overall incidence
of application site reactions of any kind was 28% (10 subjects with
13 adverse reactions).
No serious adverse reactions to ANDRODERM 2 mg/day and 4 mg/day
were reported during the clinical trial.
Table 2 shows the adverse reactions that were reported in > 3% of
122 patients in clinical studies with ANDRODERM dosage strengths
of 2.5 mg/day, 5 mg/day, and 7.5 mg/day. The most common adverse
reactions reported were application site reactions. Transient mild to
moderate erythema was observed at the site of application in the
majority of patients at some time during treatment. The overall
incidence of application site reactions of any kind was 48% (59
subjects with 107 adverse reactions).
Table 2. Adverse Reactions Seen With the Use of ANDRODERM
2.5 mg/day, 5 mg/day, or 7.5 mg/day (> 3%)
The following reactions occurred in less than 3% of patients: rash,
gastrointestinal bleeding, fatigue, body pain, pelvic pain, hypertension,
peripheral vascular disease, increased appetite, accelerated growth,
anxiety, confusion, decreased libido, paresthesia, thinking
abnormalities, vertigo, acne, bullae at application site, mechanical
irritation at application site, rash at application site, contamination of
application site, prostate carcinoma, dysuria, hematuria, impotence,
urinary incontinence, urinary tract infection, and testicular
abnormalities.
7 DRUG INTERACTIONS
7.1 Insulin
Changes in insulin sensitivity or glycemic control may occur in
patients treated with androgens. In diabetic patients, the metabolic
effects of androgens may decrease blood glucose and, therefore,
insulin requirement.
Adverse Reaction
Overall
N = 36
%
Application site pruritus 17
Application site vesicles 6
Back pain 6
Adverse Reaction
Overall
N = 122
%
Application site pruritus 37
Application site blistering 12
Application site erythema 7
Application site vesicles 6
Prostate abnormalities 5
Headache 4
Contact dermatitis to system 4
Application site burning 3
Application site induration 3
Depression 3
until you put on a new ANDRODERM patch at
your regular time.
• If your ANDRODERM patch falls off after noon,
do not put on a new one. Wait and apply your
ANDRODERM patch at your regular time.
• You should change your ANDRODERM patch every
24 hours. You should remove the old patch before
applying the new one.
• You should change (rotate) your ANDRODERM
application site every day. Do not use a site that you
have used before for at least 7 days.
• Skin redness may happen on the skin where your
ANDRODERM patch was removed. If your skin
redness does not go away, talk to your healthcare
provider. Your healthcare provider may tell you to
use an over-the-counter hydrocortisone cream on
your red skin.
• Patches that have aluminum in them can cause skin
burns at the patch site during a magnetic resonance
imaging scan (MRI). Because ANDRODERM
contains aluminum, you should take off your
ANDRODERM patch before you have an MRI.
• Do not use an ANDRODERM patch if the pouch seal
is broken or the patch is cut, damaged, or changed
in any way. Throw it away and get a new one.
Applying ANDRODERM:
• Before applying ANDRODERM, make sure that the
application area is clean, dry, and there is no
broken skin.
• Avoid areas of skin that are oily, perspire heavily, or
are covered with hair, since ANDRODERM may not
stick well to these areas.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
ANDRODERM safely and effectively. See full prescribing information
for ANDRODERM.
ANDRODERM®
(testosterone transdermal system), for topical use CIII
Initial U.S. Approval: 1995
RECENT MAJOR CHANGES
DOSAGE AND ADMINISTRATION (2.1) 10/2011
INDICATIONS AND USAGE
ANDRODERM is an androgen indicated for replacement therapy in males
for conditions associated with a deficiency or absence of endogenous
testosterone (1):
• Primary hypogonadism (congenital or acquired)
• Hypogonadotropic hypogonadism (congenital or acquired)
Important limitations of use: Safety and efficacy of ANDRODERM in males
less than 18 years old have not been established. (1, 8.4)
DOSAGE AND ADMINISTRATION
The recommended starting dose is one ANDRODERM 4 mg/day system
(not two 2 mg/day systems) applied nightly for 24 hours, delivering
approximately 4 mg of testosterone per day. (2.1)
To ensure proper dosing, approximately 2 weeks after starting therapy,
the early morning serum testosterone concentration should be measured
following system application in the previous evening. (2.1, 12.3)
Serum testosterone concentrations measured in the early morning outside
the range of 400 – 930 ng/dL require increasing the daily dose to 6 mg
(i.e., one 4 mg/day and one 2 mg/day system) or decreasing the daily dose
to 2 mg (i.e., one 2 mg/day system), maintaining nightly application. (2.1)
Patients currently maintained on ANDRODERM 2.5 mg/day systems
applied once daily may be switched to ANDRODERM 2 mg/day systems
applied once daily in the evening at the next scheduled dose. (2.1)
Patients currently maintained on ANDRODERM 5 mg/day systems applied
once daily may be switched to ANDRODERM 4 mg/day systems applied
once daily in the evening at the next scheduled dose. (2.1)
Patients currently maintained on ANDRODERM 7.5 mg (2.5 mg/day and
5 mg/day systems) applied once daily may be switched to ANDRODERM
6 mg (2 mg/day and 4 mg/day systems) applied once daily in the evening
at the next scheduled dose. (2.1)
To ensure proper dosing, approximately 2 weeks after switching therapy
an early morning serum testosterone concentration should be measured
following system application the previous evening. (2.1, 12.3)
DOSAGE FORMS AND STRENGTHS
Transdermal system: 2 mg/day and 4 mg/day. (3)
CONTRAINDICATIONS
• Men with carcinoma of the breast or known or suspected carcinoma
of the prostate. (4, 5.1)
• Pregnant or breastfeeding women. Testosterone may cause fetal harm.
(4, 8.1, 8.3)
WARNINGS AND PRECAUTIONS
• Monitor patients with benign prostatic hyperplasia (BPH) for
worsening of signs and symptoms of BPH. (5.1)
• Avoid exposure of women or children to ANDRODERM. (5.3)
• Exogenous administration of testosterone may lead to azoospermia. (5.4)
• Edema with or without congestive heart failure, may be a complication
in patients with pre-existing cardiac, renal, or hepatic disease. (5.6)
• Sleep apnea may occur in those with risk factors. (5.8)
• Monitor serum testosterone, prostate specific antigen (PSA), liver
function, lipid concentrations, hematocrit and hemoglobin periodically.
(5.1, 5.2, 5.5, 5.9)
• Skin burns have been reported at the application site in patients
wearing an aluminized transdermal system during a magnetic
resonance imaging scan (MRI). Because ANDRODERM contains
aluminum, it is recommended to remove the system before
undergoing an MRI. (5.12)
ADVERSE REACTIONS
The most common adverse reactions (incidence > 3%) are application
site reactions, and back pain. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Watson
Laboratories, Inc. at 1-800-272-5525 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
DRUG INTERACTIONS
• Androgens may decrease blood glucose and insulin requirement in
diabetic patients. (7.1)
• Changes in anticoagulant activity may be seen with androgens. More
frequent monitoring of International Normalized Ratio (INR) and
prothrombin time is recommended. (7.2)
• Use of testosterone with adrenocorticotropic hormone (ACTH) or
corticosteroids may result in increased fluid retention. Use with caution,
particularly in patients with cardiac, renal, or hepatic disease. (7.3)
USE IN SPECIFIC POPULATIONS
There are insufficient long-term safety data in geriatric patients using
ANDRODERM to assess the potential risks of cardiovascular disease and
prostate cancer. (8.5)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved
patient labeling Revised: 04/2012
Figure A Figure B
Figure C
196664-01_Physician-Patient Insert, Androderm (US) 5/23/2012 3:47 PM Page 1

10 OVERDOSAGE
No cases of overdose with ANDRODERM have been reported in clinical
trials. There is one report of acute overdosage by injection of testosterone
enanthate: testosterone concentrations of up to 11,400 ng/dL were
implicated in a cerebrovascular accident. Treatment of overdosage would
consist of discontinuation of ANDRODERM together with appropriate
symptomatic and supportive care.
11 DESCRIPTION
ANDRODERM (testosterone transdermal system) is designed to deliver
testosterone continuously for 24 hours following application to intact,
non-scrotal skin (e.g., back, abdomen, thighs, upper arms).
Two strengths of ANDRODERM are available that deliver approximately
2 mg or 4 mg of testosterone per day.
ANDRODERM has a central drug delivery reservoir surrounded by a
peripheral adhesive area. The ANDRODERM 2 mg/day system has a total
contact surface area of 32 cm2 with a 6.0 cm2 central drug delivery
reservoir containing 9.7 mg testosterone USP, dissolved in an alcohol-
based gel. The ANDRODERM 4 mg/day system has a total contact surface
area of 39 cm2 with a 12.0 cm2 central drug delivery reservoir containing
19.5 mg testosterone USP, dissolved in an alcohol-based gel.
Testosterone USP is a white, or creamy white crystalline powder or
crystals chemically described as 17ß-hydroxyandrost-4-en-3-one.
Testosterone
C19H28O2 mw 288.42
The ANDRODERM systems have six components as shown in Figure 1.
Proceeding from the top toward the surface attached to the skin, the
system is composed of (1) metallized polyester/Surlyn® (ethylene-
methacrylic acid copolymer)/ethylene vinyl acetate backing film with
alcohol resistant ink, (2) a drug reservoir of testosterone USP, alcohol
USP, glycerin USP, glycerol monooleate, methyl laurate, sodium hydroxide
NF, to adjust pH, and purified water USP, gelled with carbomer copolymer
Type B NF, (3) a permeable polyethylene microporous membrane, and (4)
a peripheral layer of acrylic adhesive surrounding the central, active drug
delivery area of the system. Prior to opening of the system and application
to the skin, the central delivery surface of the system is sealed with a
peelable laminate disc (5) composed of a five-layer laminate containing
polyester/polyesterurethane adhesive/aluminum foil/polyester-urethane
adhesive/polyethylene. The disc is attached to and removed with the
release liner (6), a silicone-coated polyester film, which is removed before
the system can be used.
Figure 1: System Schematic
The active ingredient in the system is testosterone. The remaining
components of the system are pharmacologically inactive.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Endogenous androgens, including testosterone and dihydrotestosterone
(DHT), are responsible for the normal growth and development of the
male sex organs and for maintenance of secondary sex characteristics.
These effects include the growth and maturation of prostate, seminal
vesicles, penis and scrotum; the development of male hair distribution,
such as facial, pubic, chest and axillary hair; laryngeal enlargement; vocal
cord thickening; and alterations in body musculature and fat distribution.
Testosterone and DHT are necessary for the normal development of
secondary sex characteristics. Male hypogonadism results from
insufficient secretion of testosterone and is characterized by low serum
testosterone concentrations. Signs/symptoms associated with male
hypogonadism include erectile dysfunction and decreased sexual desire,
fatigue and loss of energy, mood depression, regression of secondary
sexual characteristics, and osteoporosis.
Male hypogonadism has two main etiologies. Primary hypogonadism is
caused by defects of the gonads, such as Klinefelter Syndrome or Leydig
cell aplasia, whereas secondary hypogonadism is the failure of the
hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).
12.2 Pharmacodynamics
No specific pharmacodynamic studies were conducted using ANDRODERM.
12.3 Pharmacokinetics
Absorption
ANDRODERM delivers physiologic amounts of testosterone, producing
circulating testosterone concentrations that approximate the normal
concentration range (300 – 1030 ng/dL) seen in healthy men.
ANDRODERM provides a continuous daily dose of testosterone in a self-
contained transdermal system. Following ANDRODERM application,
testosterone is continuously absorbed during the 24-hour dosing period
with a median (range) Tmax of 8 (4-12) hours.
In a group of 34 hypogonadal men, application of two ANDRODERM
2.5 mg/day systems to the different application sites (abdomen, back,
thighs, or upper arms) delivered approximately 4 to 5 mgs of testosterone
over 24 hours.
Distribution
Circulating testosterone is primarily bound in the serum to sex hormone-
binding globulin (SHBG) and albumin. Approximately 40% of testosterone
in plasma is bound to SHBG, 2% remains unbound (free) and the rest is
bound to albumin and other proteins.
Metabolism
Testosterone is metabolized to various 17-keto steroids through two
different pathways. The major active metabolites of testosterone are
estradiol and dihydrotestosterone (DHT).
During steady-state pharmacokinetic studies in hypogonadal men treated
with ANDRODERM, the average DHT:T and E2:T ratios were approximately
1:10 and 1:200, respectively.
Excretion
There is considerable variation in the half-life of testosterone as reported
in the literature, ranging from 10 to 100 minutes. About 90% of a dose of
testosterone given intramuscularly is excreted in the urine as glucuronic
and sulfuric acid conjugates of testosterone and its metabolites; about 6%
of a dose is excreted in the feces, mostly in the unconjugated form.
Inactivation of testosterone occurs primarily in the liver.
Upon removal of the ANDRODERM systems, serum testosterone
concentrations decrease with an apparent half-life of approximately 70
minutes. Hypogonadal concentrations are reached within 24 hours
following system removal. There is no accumulation of testosterone
during continuous treatment.
Effect of Showering
In a two-way crossover study, the effects of showering on the
pharmacokinetics of total testosterone following a single application of
ANDRODERM 4 mg/day were assessed in 16 hypogonadal males.
Showering 3 hours after application of ANDRODERM increased Cavg by
0.5% and decreased Cmax by 0.4% respectively, as compared to not
showering. The systemic exposure to ANDRODERM was similar following
applications with or without showering 3 hours after application.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Testosterone has been tested by subcutaneous injection and implantation
in mice and rats. In mice, the implant induced cervical-uterine tumors,
which metastasized in some cases. There is suggestive evidence that
injection of testosterone into some strains of female mice increases their
susceptibility to hepatoma. Testosterone is also known to increase the
number of tumors and decrease the degree of differentiation of chemically
induced carcinomas of the liver in rats. Testosterone was negative in the
in vitro Ames and in the in vivo mouse micronucleus assays. The
administration of exogenous testosterone has been reported to suppress
spermatogenesis in the rat, dog and non-human primates, which was
reversible on cessation of the treatment.
14 CLINICAL STUDIES
ANDRODERM 2 mg/day and 4 mg/day were studied in a trial designed to
evaluate the use and titration of 2 mg/day and 4 mg/day systems in a
clinic setting of 40 men with hypogonadism. Thirty-eight of the 40
subjects (95%) who were enrolled into the study were white and 2
subjects were African American. Ten (25%) subjects were Hispanic and
30 (75%) were Non-Hispanic. Men were between 34 and 76 years of age
(mean: 55 years). Patients had previously been on stable therapy of
ANDRODERM 5 mg; Androgel® 2.5 g, 5 g, 7.5 g or 10 g; or Testim® 2.5 g
or 5 g daily before switching to ANDRODERM 4 mg/day.
Patients applied an ANDRODERM 4 mg/day system around 10 p.m. once
daily for 14 days, and then were titrated up to 6 mg/day or down to
2 mg/day according to a morning serum testosterone concentration
obtained at 6 a.m. on Day 8. Out of 36 patients who entered the study, 31
(86%) patients remained on the 4 mg/day dose, 4 (11%) were titrated
downward to 2 mg/day, and 1 (3%) was titrated upward to 6 mg/day
based on the Day 8 testosterone concentrations. The one patient that was
titrated to 6 mg/day discontinued from the study for a non-safety related
reason. Of the patients who were receiving ANDRODERM 5 mg/day prior
to study entry (n = 11), 10 remained at 4 mg/day after titration, and 1
was titrated down to the 2 mg/day dose.
After a total of 28 days of therapy, 34 of the 35 subjects (97%) had serum
testosterone Cavg within the normal range during the dosing period, with
the lower bound of the 95% confidence interval for this estimate being
85% (Table 3). One subject who received ANDRODERM 4 mg/day
treatment had serum testosterone Cavg below 300 ng/dL and none had Cavg
concentrations above 1030 ng/dL. The mean (SD) serum testosterone Cmax
following treatment with the 2 mg/day (N = 4) and 4 mg/day (N = 31)
systems was 648 (145) ng/dL and 696 (158) ng/dL, respectively. Table 3
summarizes testosterone Cavg categories by treatment.
Table 3. Testosterone Cavg Categories on Day 28 after One Titration on
Day 15
Figure 2 summarizes the pharmacokinetic profiles of total testosterone
in 35 patients completing 28 days of ANDRODERM treatment applied as
a starting dose of 4 mg/day for the initial 14 days followed by a possible
dose titration.
Figure 2. Mean (SD) Steady-State Serum Total Testosterone
Concentration (ng/dL) on Day 28
In separate clinical studies using the ANDRODERM 2.5 mg/day system,
1% used 2.5 mg daily, 93% of patients used 5 mg daily, and 6% used
7.5 mg daily. The hormonal effects of ANDRODERM 2.5 mg/day system
as a treatment for male hypogonadism was demonstrated in four open-
label trials that included 94 hypogonadal men, ages 15 to 65 years. In
these trials, ANDRODERM produced average morning serum testosterone
concentrations within the normal reference range in 92% of patients.
16 HOW SUPPLIED/STORAGE AND HANDLING
ANDRODERM (testosterone transdermal system) 2 mg/day.
Each system contains 9.7 mg testosterone USP for delivery of 2 mg of
testosterone per day [see Description (11)].
Cartons of 60 systems NDC 52544-076-60
ANDRODERM (testosterone transdermal system) 4 mg/day.
Each system contains 19.5 mg testosterone USP for delivery of 4 mg of
testosterone per day [see Description (11)].
Cartons of 30 systems NDC 52544-077-30
Store at 20-25°C (68-77°F). [See USP controlled room temperature.]
Apply to skin immediately upon removal from the protective pouch. Do
not store outside the pouch provided. Damaged systems should not be
used. The drug reservoir may be burst by excessive pressure or heat.
Discard systems in household trash in a manner that prevents accidental
application or ingestion by children, pets or others.
17 PATIENT COUNSELING INFORMATION
See “FDA-approved patient labeling (Patient Information.)”
Patients should be informed of the following information:
17.1 Use in Men with Known or Suspected Prostate or Breast Cancer
Men with known or suspected prostate or breast cancer should not use
ANDRODERM[seeContraindications(4)andWarningsandPrecautions(5.1)].
17.2 Potential Adverse Reactions with Androgens
Patients should be informed that treatment with androgens may lead to
adverse reactions that include:
• Changes in urinary habits such as increased urination at night, trouble
starting your urine stream, passing urine many times during the day,
having an urge that you have to go to the bathroom right away, having
a urine accident, being unable to pass urine and having a weak urine
flow
• Breathing disturbances, including those associated with sleep, or
excessive daytime sleepiness
• Too frequent or persistent erections of the penis
• Nausea, vomiting, changes in skin color, or ankle swelling
17.3 Patients Should be Advised of these Application Instructions
• ANDRODERM should not be applied to the scrotum.
• ANDRODERM should not be applied over a bony prominence or on a
part of the body that could be subject to prolonged pressure during
sleep or sitting. Application to these sites has been associated with
burn-like blister reactions.
• ANDRODERM does not have to be removed during sexual intercourse,
nor while taking a shower or bath.
• ANDRODERM systems should be applied nightly. The site of
application should be rotated, with an interval of 7 days between
applications to the same site.
• If the ANDRODERM system becomes loose, smooth it down again by
rubbing your finger firmly around the edges. If a patch falls off before
noon, replace it with a fresh patch and wear it until you apply a fresh
patch(es) that evening. If it falls off later in the day, do not replace it
until you apply a fresh patch(es) that evening. If it falls off do not tape
ANDRODERM to skin.
• If patients or caregivers experience difficulty separating the patch from
the release liner or observe transfer of adhesive to the liner, tearing
and/or other damage to the patch during removal from the liner, the
patch should be discarded, and a new patch should be applied.
• ANDRODERM should be applied immediately after opening the
individual pouch and removing the protective liner. Do not use if the
individual pouch seal is broken or if the patch appears to be damaged.
Do not cut patches. Only intact patches should be applied.
• Strenuous exercise or excessive perspiration may loosen a patch or
cause it to fall off.
• Skin burns have been reported at the application site in patients wearing
an aluminized transdermal system during a magnetic resonance
imaging scan (MRI). Because ANDRODERM contains aluminum, it is
recommended to remove the system before undergoing an MRI.
• Avoid swimming or showering until 3 hours following application of
ANDRODERM [see Dosage and Administration (2) and Clinical
Pharmacology (12.3)].
For all medical inquiries contact:
WATSON
Medical Communications
Parsippany, NJ 07054
800-272-5525
Manufactured By:
Watson Laboratories, Inc.
Salt Lake City, UT 84108 USA
Distributed By:
Watson Pharma, Inc.
Revised: April 2012 196664-01
7.2 Oral Anticoagulants
Changes in anticoagulant activity may be seen with androgens. More
frequent monitoring of INR and prothrombin time is recommended in
patients taking anticoagulants, especially at the initiation and
termination of androgen therapy.
7.3 Corticosteroids
The concurrent use of testosterone with ACTH or corticosteroids may
result in increased fluid retention and should be monitored, particularly
in patients with cardiac, renal or hepatic disease.
7.4 Triamcinolone
• The topical administration of 0.1% triamcinolone cream to the skin
under the central drug reservoir prior to the application of the
ANDRODERM system did not significantly alter transdermal
absorption of testosterone; however, the rate of complete
adherence was lower.
• Pretreatment with triamcinolone ointment formulation significantly
reduced testosterone absorption from the ANDRODERM system.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category X [see Contraindications (4)] — ANDRODERM
is contraindicated during pregnancy or in women who may become
pregnant. Testosterone is teratogenic and may cause fetal harm.
Exposure of a female fetus to androgens may result in varying degrees
of virilization. If this drug is used during pregnancy, or if the patient
becomes pregnant while taking this drug, the patient should be
apprised of the potential hazard to a fetus.
8.3 Nursing Mothers
Although it is not known how much testosterone transfers into human
milk, ANDRODERM is contraindicated in nursing women because of
the potential for serious adverse reactions in nursing infants.
Testosterone and other androgens may adversely affect lactation [see
Contraindications (4)].
8.4 Pediatric Use
Safety and efficacy of ANDRODERM have not been established in
males less than 18 years of age. Improper use may result in
acceleration of bone age and premature closure of epiphyses.
8.5 Geriatric Use
There have not been sufficient numbers of geriatric patients involved
in controlled clinical studies utilizing ANDRODERM to determine
whether efficacy in those over 65 years of age differs from younger
patients. Additionally, there are insufficient long-term safety data in
geriatric patients utilizing ANDRODERM to assess a potential
incremental risk of cardiovascular disease and prostate cancer.
8.6 Renal Impairment
No studies were conducted in patients with renal impairment.
8.7 Hepatic Impairment
No studies were conducted in patients with hepatic impairment.
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
ANDRODERM contains testosterone, a Schedule III controlled
substance under the Anabolic Steroids Control Act.
9.2 Abuse
Anabolic steroids, such as testosterone, are abused. Abuse is often
associated with adverse physical and psychological effects.
9.3 Dependence
Although drug dependence is not documented in individuals using
therapeutic doses of anabolic steroids for approved indications,
dependence is observed in some individuals abusing high doses of
anabolic steroids. In general, anabolic steroid dependence is
characterized by any three of the following:
• Taking more drug than intended
• Continued drug use despite medical and social problems
• Significant time spent in obtaining adequate amounts of drug
• Desire for anabolic steroids when supplies of the drug are interrupted
• Difficulty in discontinuing use of the drug despite desires and
attempts to do so
• Experience of withdrawal syndrome upon discontinuation of
anabolic steroid use
2. Remove the protective
plastic liner and silver
disc from the patch.
Hold on to the tabs on
the patch and the
protective plastic liner
and gently pull the two
apart to remove the
plastic liner and silver
disc from the patch
(See Figure D).
This will expose the
adhesive and central
reservoir area on the
patch (See Figure E).
• The patch should
pull off easily from
the protective plastic
liner. Do not use the
ANDRODERM patch
if the liner is hard to pull off. Throw away the
ANDRODERM patch and get a new one.
3. Check the protective plastic liner. You should
not see any glue (adhesive) sticking to the liner.
Do not use the ANDRODERM patch if you see any
adhesive sticking to the liner. Throw away the
ANDRODERM patch and get a new one.
Throw away the clear plastic liner and silver disc.
4. Apply the patch. Apply the patch right away after
you remove the patch from the protective pouch
and remove the plastic liner.
Place the patch flat on the skin with the sticky side
down and firmly press around the edges. Make sure
that the patch sticks well to the skin.
What are the possible side effects of ANDRODERM?
ANDRODERM can cause serious side effects including:
• If you already have an enlargement of your
prostate gland your signs and symptoms may get
worse while using ANDRODERM. This can include:
• increased urination at night
• trouble starting your urine stream
• having to pass urine many times during the day
• having an urge that you have to go to the bathroom
right away
• having a urine accident
• being unable to pass urine or weak urine flow
• Possible increased risk of prostate cancer. Your
healthcare provider should check you for prostate
cancer or any other prostate problems before you
start and while you use ANDRODERM.
• Blood clots in the legs. This can include pain,
swelling or redness of your legs.
• In large doses ANDRODERM may lower your
sperm count.
• Swelling of your ankles, feet, or body, with or
without heart failure.
• Enlarged or painful breasts.
• Problems breathing while you sleep (sleep apnea).
Call your healthcare provider right away if you have any
of the serious side effects listed above.
The most common side effects of ANDRODERM include:
• skin redness, irritation, burning, or blisters where
ANDRODERM is applied
• back pain
• depression
• headache
• prostate abnormalities
Other side effects include more erections than are
normal for you or erections that last a long time.
Tell your healthcare provider if you have any side effect
that bothers you or that does not go away.
These are not all the possible side effects of
ANDRODERM. For more information, ask your
healthcare provider or pharmacist.
Call your healthcare provider for medical advice about
side effects. You may report side effects to FDA at
1-800-FDA-1088.
How should I store ANDRODERM?
• Keep ANDRODERM at room temperature between
68°F to 77°F (20°C to 25°C).
• Keep ANDRODERM in its sealed protective foil pouch
until you are ready to use it. Do not remove an
ANDRODERM patch from the pouch until you are
ready to use it.
• Safely throw away your used ANDRODERM patch.
Fold your used ANDRODERM patch in half so that
Cavg Category
Current Testosterone User
N = 35
300 - 1030 ng/dL (n (%)(95% CI))
34/35 (97%)
(85%, 100%)
< 300 ng/dL (n (%)) 1/35 (3%)
the sticky sides stick together. Throw away your
used ANDRODERM patch in the household trash.
• Be careful to prevent accidental exposure of
ANDRODERM to children or pets.
General information about the safe and effective use
of ANDRODERM
Medicines are sometimes prescribed for purposes other
than those listed in a Patient Information leaflet. Do not
use ANDRODERM for a condition for which it was not
prescribed. Do not give ANDRODERM to other people,
even if they have the same symptoms you have. It may
harm them.
This Patient Information leaflet summarizes the most
important information about ANDRODERM. If you
would like more information, talk to your healthcare
provider. You can ask your pharmacist or healthcare
provider for information about ANDRODERM that is
written for health professionals.
For more information, go to www.androderm.com or call
1-800-272-5525. If you have questions or concerns
about your ANDRODERM treatment, ask your healthcare
provider or pharmacist.
What are the ingredients in ANDRODERM?
Active ingredient: testosterone
Inactive ingredients:
• Backing Film: Metallized polyester/Surlyn®
(ethylene-methacrylic acid copolymer)/ethylene vinyl
acetate backing film with alcohol resistant ink
• Drug Reservoir: Testosterone USP, alcohol USP,
glycerin USP, glycerol monooleate, methyl laurate,
sodium hydroxide NF, purified water USP, gelled with
carbomer copolymer Type B NF
• Microporous Membrane: a permeable polyethylene
microporous membrane
• Adhesive: a peripheral layer of acrylic adhesive
surrounding the central, active drug delivery area of
the system
• Disc: a five-layer laminate containing
polyester/polyesturethane adhesive/aluminum
foil/polyester-urethane adhesive/polyethylene
• Release Liner: a silicone-coated polyester film,
which is removed before the system can be used
For all medical inquiries contact:
WATSON
Medical Communications
Parsippany, NJ 07054
800-272-5525
Manufactured By:
Watson Laboratories, Inc.
Salt Lake City, UT 84108 USA
Distributed By:
Watson Pharma, Inc.
This Patient Information has been approved by the
U.S. Food and Drug Administration
Issued: 04/2012 196664-01
Figure D
Figure E
Printedat
Magnification
BarCode:Manufacturing
Type:Code39
Magnif.:100%
BWR:2.5mils
Encoded:196664-01
BlackInformation/
Dieline
Description:Physician-PatientInsert,AndrodermTTS(US)
ItemNo.(JDE):205052DrawingNo.(Artwork):196664-01PLECRNo.:120014aS
TechnicalDrawingNo.:PharmLithoRTA#97Artist:K.Kynaston
Dimensions:18.000"Wx15.000"H-Flat;3.000"Wx2.500"H-FoldedProprietaryLabeling•WatsonLaboratories,Inc.•SaltLakeCity,UT84108•(801)588-6200
ApprovalSignaturesICE
196664-01_Physician-Patient Insert, Androderm (US) 5/23/2012 3:47 PM Page 2

Pharmaceutical Samples

More Related Content

Viewers also liked (15)

Similar to Pharmaceutical Samples (20)

Pharmaceutical Samples